Shandong Lukang Pharmaceutical (600789.SH) announced that recently, its controlling subsidiary Shandong Lukang Pharmaceutical Group Sate...
According to the Zhitong Finance APP, Shandong Lukang Pharmaceutical (600789.SH) recently announced that its controlling subsidiary Shandong Lukang Pharmaceutical Group Sate Ltd. (hereinafter referred to as Sate Company) has received the "Drug Registration Certificate" for levofloxacin hydrochloride sodium chloride injection (Approval No.: 2024S02369) issued by the National Medical Products Administration. This drug is a generic drug approved in the new registration category 4, considered to have passed the consistency evaluation of generic drug quality and efficacy.
Moxifloxacin is a broad-spectrum antibacterial drug with bactericidal activity belonging to the 8-methoxy fluoroquinolone class. In vitro, moxifloxacin has shown broad-spectrum antibacterial activity against Gram-positive bacteria, Gram-negative bacteria, anaerobes, acid-resistant bacteria, and atypical microorganisms such as mycoplasma, chlamydia, and legionella, with a bactericidal mechanism of action by interfering with topoisomerase II and IV. The levofloxacin hydrochloride sodium chloride injection has obtained the "Drug Registration Certificate," which will further enrich the product pipeline of Sate Company, enhancing its market competitiveness.
